a 66-year-old woman
PLA2R-positive primary membranous nephropathy (stage III), refractory after anti-rituximab antibody-associated rituximab failure
A 66-year-old woman had membranous nephropathy that tested positive for the PLA2R antibody. She was treated with rituximab, but her body made antibodies against rituximab and the drug stopped working. Her B cells came back, the drug was undetectable in her blood, and her urine protein got worse. A kidney biopsy confirmed stage 3 membranous nephropathy. Her doctors then gave her obinutuzumab, another antibody that targets B cells. It fully cleared the B cells in her blood and reached a good blood level, and she reached both immune and clinical remission within 8.5 months, even though she still had the anti-rituximab antibodies.
In one woman whose kidney disease kept getting worse after rituximab stopped working, switching to a related drug called obinutuzumab brought both her immune markers and her kidney disease into remission within about 8 and a half months.
- Her membranous nephropathy was driven by the PLA2R antibody, and rituximab was tried first because it is the standard antibody treatment for this disease.
- Rituximab failed because her body made anti-rituximab antibodies (ARA), so her B cells came back, the drug vanished from her blood, and her urine protein worsened.
- Obinutuzumab, a different anti-CD20 antibody, fully wiped out her circulating B cells and reached a proper drug level in her blood, unlike rituximab.
- She reached both immune remission and clinical remission within 8.5 months even though the anti-rituximab antibodies never went away.
- The authors argue that measuring drug levels, checking for anti-rituximab antibodies, and tracking B cells all help guide treatment when the first drug fails.
Why it might work
In this disease, immune cells called B cells make the harmful PLA2R antibody that damages the kidney's filters and lets protein leak into the urine. Rituximab normally clears out those B cells, but her body learned to block rituximab, so the B cells survived and the disease pushed on. Obinutuzumab targets the same B-cell marker (CD20) but is built differently, so the anti-rituximab antibodies did not block it. It cleared her B cells completely and stayed at a working level in her blood, which the paper links to her immune markers settling and her kidney disease going into remission.
The honest limits
- This is a single patient (n=1), so it cannot tell us how often obinutuzumab works after rituximab fails.
- The abstract reports remission within 8.5 months but gives no long-term follow-up, so we do not know if it lasted.
- The abstract does not give exact numbers for her proteinuria, kidney function (GFR), or antibody titers, so the size of her improvement is not spelled out.
- The abstract lists no funding or conflict-of-interest disclosures, so none can be reported here either way.
- If rituximab is not working for me, could anti-rituximab antibodies be the reason, and can that be tested?
- Would checking my drug levels and B-cell counts help decide whether to switch treatments?
- Is obinutuzumab an option for my type of membranous nephropathy, and what are its risks for someone with my kidney function?